Anticoagulant Therapy for Venous Thromboembolism in Cancer
Mené respectivement sur 576 et 579 patients atteints d’un cancer, cet essai randomisé compare l’efficacité de l’apixaban dispensé par voie orale et de la deltaparine dispensée par voie sous-cutanée pour traiter une maladie thromboembolique veineuse (durée du traitement : 6 mois)
Direct oral anticoagulants were introduced for the treatment for acute venous thromboembolism just over a decade ago. Unlike warfarin, these drugs are given in fixed doses and do not require laboratory monitoring of the anticoagulant effect. Although direct oral anticoagulants are similar to warfarin in efficacy, they are more convenient to use and are associated with a lower risk of major bleeding, particularly intracranial hemorrhage. These factors prompted a change in practice guidelines to recommend the use of direct oral anticoagulants as the first-line therapy over warfarin and transformed outpatient treatment for the majority of patients with acute venous thromboembolism (…)
The New England Journal of Medicine , éditorial, 2019